Small players with big roles: MicroRNAs as targets to inhibit breast cancer progression

Current Drug Targets

Volumn 11, Issue 9, 2010, Pages 1059-1073

  Greene, Stephanie B ^a,b   Herschkowitz, Jason I ^a   Rosen, Jeffrey M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; miRNA; Novel therapeutics; Stem cells

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MICRORNA; MICRORNA 107; MICRORNA 10A; MICRORNA 10B; MICRORNA 125A; MICRORNA 125B; MICRORNA 126; MICRORNA 130A; MICRORNA 143; MICRORNA 145; MICRORNA 146A; MICRORNA 146B; MICRORNA 15; MICRORNA 150; MICRORNA 154; MICRORNA 16; MICRORNA 17 5P; MICRORNA 21; MICRORNA 22; MICRORNA 26A; MICRORNA 26B; MICRORNA 29B; MICRORNA 30A 5P; MICRORNA 30B; MICRORNA 30C; MICRORNA 30D; MICRORNA 31; MICRORNA 9; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER STEM CELL; CELL PROLIFERATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; ONCOGENE; PROTEIN EXPRESSION; PROTEIN TARGETING; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UPREGULATION;

BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; ONCOGENES; PROGNOSIS;

EID: 78651338744     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010792006762     Document Type: Article

References (173)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281.
2. Lewis BP, Burge CB Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120(1): 15-20.
3. Kim VN Nam JW. Genomics of microRNA. Trends Genet 2006; 22(3): 165-73.
4. Davis BN Hata A. Regulation of MicroRNA Biogenesis: A miRiad of mechanisms. Cell Commun Signal 2009; 7: 18.
5. Berezikov E, Chung WJ, Willis J, Cuppen E Lai EC. Mammalian mirtron genes. Mol Cell 2007; 28(2): 328-36.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
7. Friedman RC, Farh KK, Burge CB Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19(1): 92-105.
8. Cougot N, Babajko S Seraphin B. Cytoplasmic foci are sites of mRNA decay in human cells. J Cell Biol 2004; 165(1): 31-40.
9. Liu J, Valencia-Sanchez MA, Hannon GJ Parker R. MicroRNAdependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 2005; 7(7): 719-23.
10. Sen GL Blau HM. Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies. Nat Cell Biol 2005; 7(6): 633-6.
11. Ghosh T, Soni K, Scaria V, Halimani M, Bhattacharjee C Pillai B. MicroRNA-mediated up-regulation of an alternatively polyadenylated variant of the mouse cytoplasmic {beta}-actin gene. Nucleic Acids Res 2008; 36(19): 6318-32.
12. Vasudevan S, Tong Y Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318(5858): 1931-4.
13. Kanellopoulou C, Muljo SA, Kung AL, et al. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev 2005; 19(4): 489-501.
14. Andl T, Murchison EP, Liu F, et al. The miRNA-processing enzyme dicer is essential for the morphogenesis and maintenance of hair follicles. Curr Biol 2006; 16(10): 1041-9.
15. Bernstein E, Kim SY, Carmell MA, et al. Dicer is essential for mouse development. Nat Genet 2003; 35(3): 215-7.
16. Muljo SA, Ansel KM, Kanellopoulou C, Livingston DM, Rao A Rajewsky K. Aberrant T cell differentiation in the absence of Dicer. J Exp Med 2005; 202(2): 261-9.
17. Sood P, Krek A, Zavolan M, Macino G Rajewsky N. Cell-typespecific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci USA 2006; 103(8): 2746-51.
18. Houbaviy HB, Murray MF Sharp PA. Embryonic stem cell-specific MicroRNAs. Develop Cell 2003; 5(2): 351-8.
19. Ivey KN, Muth A, Arnold J, et al. MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell 2008; 2(3): 219-29.
20. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006; 38(2): 228-33.
21. Chen CZ, Li L, Lodish HF Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303(5654): 83-6.
22. Yi R, Poy MN, Stoffel M Fuchs E. A skin microRNA promotes differentiation by repressing 'stemness'. Nature 2008; 452(7184): 225-9.
23. Krichevsky AM, Sonntag KC, Isacson O Kosik KS. Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells (Dayton, Ohio) 2006; 24(4): 857-64.
24. Smirnova L, Grafe A, Seiler A, Schumacher S, Nitsch R Wulczyn FG. Regulation of miRNA expression during neural cell specification. Eur J Neurosci 2005; 21(6): 1469-77.
25. Reya T, Morrison SJ, Clarke MF Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414(6859): 105-11.
26. Daniel CW, De Ome KB, Young JT, Blair PB Faulkin LJ, Jr. The in vivo life span of normal and preneoplastic mouse mammary glands: a serial transplantation study. Proc Natl Acad Sci USA 1968; 61(1): 53-60.
27. Deome KB, Faulkin LJ, Jr., Bern HA Blair PB. Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Res 1959; 19(5): 515-20.
28. Young LJ, Medina D, DeOme KB, Daniel CW. The influence of host and tissue age on life span and growth rate of serially transplanted mouse mammary gland. Exp Gerontol 1971; 6(1): 49-56.
29. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature 2006; 439(7072): 84-8.
30. Stingl J, Eirew P, Ricketson I, et al. Purification and unique properties of mammary epithelial stem cells. Nature 2006; 439(7079): 993-7.
31. Moraes RC, Zhang X, Harrington N, et al. Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development 2007; 134(6): 1231-42.
32. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1(5): 555-67.
33. Lim E, Vaillant F, Wu D, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15(8): 907-13.
34. Georgantas RW, 3rd, Hildreth R, Morisot S, et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007; 104(8): 2750-5.
35. Greene SB, Gunaratne PH, Hammond SM Rosen JM. A putative role for microRNA-205 in mammary epithelial cell progenitors. J Cell Sci 2010; 123(Pt 4): 606-18.
36. Ibarra I, Erlich Y, Muthuswamy SK, Sachidanandam R Hannon GJ. A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells. Genes Dev 2007; 21(24): 3238-43.
37. Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA- 200c links breast cancer stem cells with normal stem cells. Cell 2009; 138(3): 592-603.
38. Bartel DP Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nature Rev Genet 2004; 5: 396.
39. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101(9): 2999-3004.
40. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435(7043): 828-33.
41. Kluiver J, Haralambieva E, de Jong D, et al. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosomes Cancer 2006; 45(2): 147-53.
42. Blenkiron C, Goldstein LD, Thorne NP, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumour subtype. Genome Biol 2007; 8(10): R214.
43. Jiang J, Lee EJ, Gusev Y Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 2005; 33(17): 5394-403.
44. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70.
45. Mattie MD, Benz CC, Bowers J, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006;5:24.
46. Adams BD, Furneaux H White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol 2007; 21(5): 1132-47.
47. Kondo N, Toyama T, Sugiura H, Fujii Y Yamashita H. miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 2008; 68(13): 5004-8.
48. Zhao JJ, Lin J, Yang H, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008; 283(45): 31079-86.
49. Miller TE, Ghoshal K, Ramaswamy B, et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008; 283(44): 29897-903.
50. Di Leva G, Gasparini P, Piovan C, et al. MicroRNA Cluster 221-222 and Estrogen Receptor {alpha} Interactions in Breast Cancer. J Natl Cancer Inst 2010; 102(10): 706-21.
51. Xiong J, Yu D, Wei N, et al. An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J 2010; 277(7): 1684-94.
52. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100(9): 672-9.
53. Phillips TM, McBride WH Pajonk F. The response of CD24(- /low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98(24): 1777-85.
54. Zhang M, Behbod F, Atkinson RL, et al. Identification of tumorinitiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008; 68(12): 4674-82.
55. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435(7043): 834-8.
56. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103(7): 2257-61.
57. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100(7): 3983-8.
58. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131(6): 1109-23.
59. Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9(6): 582-9.
60. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10(5): 593-601.
61. Korpal M, Lee ES, Hu G Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283(22): 14910-4.
62. Park SM, Gaur AB, Lengyel E Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22(7): 894-907.
63. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133(4): 704-15.
64. Iliopoulos D, Polytarchou C, Hatziapostolou M, et al. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2009; 2(92): ra62.
65. Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11(12): 1487-95.
66. Clurman BE Hayward WS. Multiple proto-oncogene activations in avian leukosis virus-induced lymphomas: evidence for stagespecific events. Mol Cell Biol 1989; 9(6): 2657-64.
67. Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007; 316(5824): 608-11.
68. Metzler M, Wilda M, Busch K, Viehmann S Borkhardt A. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 2004; 39(2): 167-9.
69. Jiang S, Zhang HW, Lu MH, et al. MicroRNA-155 Functions as an OncomiR in Breast Cancer by Targeting the Suppressor of Cytokine Signaling 1 Gene. Cancer Res 2010; 70(8): 3119-27.
70. Gaur A, Jewell DA, Liang Y, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007; 67(6): 2456-68.
71. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133(2): 647-58.
72. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008; 283(2): 1026-33.
73. Zhu S, Wu H, Wu F, Nie D, Sheng S Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008; 18(3): 350-9.
74. Zhu S, Si ML, Wu H Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007; 282(19): 14328-36.
75. Papagiannakopoulos T, Shapiro A Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 2008; 68(19): 8164-72.
76. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99(24): 15524-9.
77. Calin GA, Cimmino A, Fabbri M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008; 105(13): 5166-71.
78. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282(2): 1479-86.
79. Li W, Duan R, Kooy F, Sherman SL, Zhou W Jin P. Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet 2009; 46(5): 358-60.
80. Iorio MV, Casalini P, Piovan C, et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009; 69(6): 2195-200.
81. Wu H, Zhu S Mo YY. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res 2009; 19(4): 439-48.
82. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65(21): 9628-32.
83. Yu Z, Wang C, Wang M, et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 2008; 182(3): 509-17.
84. Woods K, Thomson JM Hammond SM. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem 2007; 282(4): 2130-4.
85. Petrocca F, Visone R, Onelli MR, et al. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008; 13(3): 272-86.
86. Ventura A, Young AG, Winslow MM, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008; 132(5): 875-86.
87. Novotny GW, Sonne SB, Nielsen JE, et al. Translational repression of E2F1 mRNA in carcinoma in situ and normal testis correlates with expression of the miR-17-92 cluster. Cell Death Differ 2007; 14(4): 879-82.
88. Hossain A, Kuo MT Saunders GF. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 2006; 26(21): 8191-201.
89. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV Mendell JT. c- Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435(7043): 839-43.
90. Avril-Sassen S, Goldstein LD, Stingl J, et al. Characterisation of microRNA expression in post-natal mouse mammary gland development. BMC Genomics 2009; 10: 548.
91. Takwi A Li Y. The p53 Pathway Encounters the MicroRNA World. Curr Genomics 2009; 10(3): 194-7.
92. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447(7148): 1130-4.
93. Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009; 106(9): 3207-12.
94. Park SY, Lee JH, Ha M, Nam JW Kim VN. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009; 16(1): 23-9.
95. Braun CJ, Zhang X, Savelyeva I, et al. p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest. Cancer Res 2009; 68(24): 10094-104.
96. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S Miyazono K. Modulation of microRNA processing by p53. Nature 2009; 460(7254): 529-33.
97. Hurst DR, Edmonds MD Welch DR. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 2009; 69(19): 7495-8.
98. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer 2009; 9(4): 293-302.
99. Dykxhoorn DM, Wu Y, Xie H, et al. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS ONE 2009; 4(9): e7181.
100. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009 [Epub ahead of print].
101. Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12(3): 247-56.
102. Edmonds MD, Hurst DR, Vaidya KS, Stafford LJ, Chen D Welch DR. Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer 2009; 125(8): 1778-85.
103. Ma L, Teruya-Feldstein J Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449(7163): 682-8.
104. Moriarty CH, Pursell B Mercurio AM. miR-10b targets Tiam1: Implications for Rac activation and carcinoma migration. J Biol Chem 2010 [Epub ahead of print].
105. Ma L, Reinhardt F, Pan E, et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 2010; 28(4): 341-7.
106. Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451(7175): 147-52.
107. Zhang J, Du YY, Lin YF, et al. The cell growth suppressor, mir- 126, targets IRS-1. Biochem Biophys Res Commun 2008; 377(1): 136-40.
108. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J Benz CC. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008; 27(42): 5643-7.
109. Valastyan S, Reinhardt F, Benaich N, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137(6): 1032-46.
110. Valastyan S, Benaich N, Chang A, Reinhardt F Weinberg RA. Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. Genes Dev 2009; 23(22): 2592-7.
111. Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nature Cell Biol 2008; 10(2): 202-10.
112. Sachdeva M Mo YY. MicroRNA-145 Suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010; 70(1): 378-87.
113. Liu S, Goldstein RH, Scepansky EM Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. Cancer Res 2009; 69(22): 8742-51.
114. Yu Z, Willmarth NE, Zhou J, et al. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci USA 2010; 107(18): 8231-6.
115. Baffa R, Fassan M, Volinia S, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009; 219(2): 214-21.
116. Camps C, Buffa FM, Colella S, et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008; 14(5): 1340-8.
117. Crosby ME, Kulshreshtha R, Ivan M Glazer PM. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res 2009; 69(3): 1221-9.
118. Kulshreshtha R, Ferracin M, Wojcik SE, et al. A microRNA signature of hypoxia. Mol Cell Biol 2007; 27(5): 1859-67.
119. Foekens JA, Sieuwerts AM, Smid M, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 2008; 105(35): 13021-6.
120. Fasanaro P, D'Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008; 283(23): 15878-83.
121. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab 2009; 10(4): 273-84.
122. Cha ST, Chen PS, Johansson G, et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res. 2010; 70(7): 2675-85.
123. Chin LJ, Ratner E, Leng S, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 2008; 68(20): 8535-40.
124. Song F, Zheng H, Liu B, et al. An miR-502-binding site singlenucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res 2009; 15(19): 6292-300.
125. Tchatchou S, Jung A, Hemminki K, et al. A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. Carcinogenesis 2009; 30(1): 59-64.
126. Nicoloso MS, Sun H, Spizzo R, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res 2010; 70(7): 2789-98.
127. Hoffman AE, Zheng T, Yi C, et al. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res 2009; 69(14): 5970-7.
128. Yang R, Schlehe B, Hemminki K, et al. A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res Treat 2010; 121(3): 693-702.
129. Hutvagner G, Simard MJ, Mello CC, Zamore PD. Sequencespecific inhibition of small RNA function. PLoS Biol 2004; 2(4): E98.
130. Meister G, Landthaler M, Dorsett Y, Tuschl T. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 2004; 10(3): 544-50.
131. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65(14): 6029-33.
132. Orom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006; 372: 137-41.
133. Wahlestedt C, Salmi P, Good L, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 2000; 97(10): 5633-8.
134. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438(7068): 685-9.
135. Krutzfeldt J, Kuwajima S, Braich R, et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 2007; 35(9): 2885-92.
136. Fontana L, Fiori ME, Albini S, et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS ONE 2008; 3(5): e2236.
137. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456(7224): 980-4.
138. Ren XP, Wu J, Wang X, et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heatshock protein 20. Circulation 2009; 119(17): 2357-66.
139. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007 May; 13(5): 613-8.
140. Si ML, Zhu S, Wu H, Lu Z, Wu F Mo YY. miR-21-mediated tumor growth. Oncogene 2007; 26(19): 2799-803.
141. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105(35): 13027-32.
142. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120(5): 635-47.
143. Kumar MS, Lu J, Mercer KL, Golub TR Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39(5): 673-7.
144. Lee YS Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007; 21(9): 1025-30.
145. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67(16): 7713-22.
146. Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008; 7(6): 759-64.
147. Blower PE, Chung JH, Verducci JS, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008; 7(1): 1-9.
148. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010 [Epub ahead of print].
149. Sandberg R, Neilson JR, Sarma A, Sharp PA Burge CB. Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites. Science 2008; 320(5883): 1643-7.
150. Mayr C Bartel DP. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 2009; 138(4): 673-84.
151. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100(14): 8418-23.
152. Sempere LF, Christensen M, Silahtaroglu A, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007; 67(24): 11612-20.
153. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102(39): 13944-9.
154. Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14(11): 1271-7.
155. Mott JL, Kobayashi S, Bronk SF Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26(42): 6133-40.
156. Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006; 66(24): 11590-3.
157. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007; 104(40): 15805-10.
158. Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO, Yasuda J. MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS ONE 2009; 4(8): e6677.
159. Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Developmental Cell 2008; 15(2): 272-84.
160. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008; 111(3): 1217-26.
161. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1(12): 882-91.
162. Esau C, Kang X, Peralta E, et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 2004; 279(50): 52361-5.
163. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009; 69(4): 1279-83.
164. Labbaye C, Spinello I, Quaranta MT, et al. A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol 2008; 10(7): 788-801.
165. Taganov KD, Boldin MP, Chang KJ Baltimore D. NF-kappaBdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103(33): 12481-6.
166. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005; 102(52): 19075-80.
167. Lin YC, Kuo MW, Yu J, et al. c-Myb is an evolutionary conserved miR-150 target and miR-150/c-Myb interaction is important for embryonic development. Mol Biol Evol 2008; 25(10): 2189-98.
168. Segura MF, Hanniford D, Menendez S, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 2009; 106(6): 1814-9.
169. Gandellini P, Folini M, Longoni N, et al. miR-205 Exerts tumorsuppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009; 69(6): 2287-95.
170. Fasanaro P, Greco S, Lorenzi M, et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem 2009; 284(50): 35134-43.
171. Yuen T, Ruf F, Chu T Sealfon SC. Microtranscriptome regulation by gonadotropin-releasing hormone. Mol Cell Endocrinol 2009; 302(1): 12-7.
172. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68(2): 425-33.
173. Lee KH, Goan YG, Hsiao M, et al. MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in hu/man esophageal cancer. Exp Cell Res 2009; 315(15): 2529-38.